Clinical Trials

argenx has clinical trials ongoing across its differentiated antibody pipeline

Efgartigimod

Myasthenia Gravis (MG)

ADAPT

Phase 3 trial of IV efgartigimod for the treatment of generalized MG. Completed.
Program: Efgartigimod

Primary Immune Thrombocytopenia (ITP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Pemphigus Vulgaris (PV)

Cusatuzumab

Acute Myeloid Leukemia (AML)

CULMINATE

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
Program: Cusatuzumab

Cusatuzumab Combination (AML)

Cusatuzumab in Combination with Background Therapy for the Treatment of Participants with Acute Myeloid Leukemia
Program: Cusatuzumab

Cusatuzumab with Japanese Participants

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants with Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome who are not Candidates for Intensive Treatment
Program: Cusatuzumab

ARGX-117

Multifocal Motor Neuropathy

ARGX-117

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
Program: ARGX-117